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1276Objectives: Although refractory to chemotherapy, metastatic melanoma may respond to adoptive immunother-
apy. As novel treatments evolve, surgeons may be asked to perform metastasectomy not only for palliation or
potential cure but also for isolation of tumor-infiltrating lymphocytes. This study was undertaken to examine
outcomes of patients with melanoma undergoing thoracic metastasectomy in preparation for investigational
immunotherapy.
Methods: A retrospective review identified 107 consecutive patients who underwent 116 thoracic metastasec-
tomy procedures from April 1998 to July 2009. Indications for surgical intervention included procurement of
tumor-infiltrating lymphocytes, rendering of patients to no evaluable disease status, palliation, and diagnosis.
Response Evaluation Criteria in Solid Tumors criteria were used to assess tumor response.
Results: Thoracotomy, lobectomy, and video-assisted thoracoscopic surgery with nonanatomic resection were
the most common procedures. Major complications included 1 death and 1 coagulopathy-induced hemothorax.
Seventeen patients were rendered to no evaluable disease status. Virtually all patients with residual disease had
tumor specimens cultured for tumor-infiltrating lymphocytes; approximately 70% of tumor-infiltrating lympho-
cyte cultures exhibited antitumor reactivity. Of the 91 patients with residual or recurrent disease, 24 (26%)
underwent adoptive cell transfer of tumor-infiltrating lymphocytes, of whom 7 exhibited objective responses
(29% response rate and 8% based on intent to treat). Rapid disease progression precluded tumor-infiltrating lym-
phocyte therapy in most cases. Actuarial 1- and 5-year survival rates for patients rendered to no evaluable disease
status or receiving or not receiving tumor-infiltrating lymphocytes were 93% and 76%, 64% and 33%, and 43%
and 0%, respectively.
Conclusions: Relatively few patients currently having thoracic metastasectomy undergo adoptive cell transfer.
Continued refinement of tumor-infiltrating lymphocyte expansion protocols and improved patient selection might
increase the number of patients with melanoma benefiting from these interventions. (J Thorac Cardiovasc Surg
2010;140:1276-82)Malignant melanoma is a highly lethal disease, the incidence
of which continues to increase at an alarming rate.1 In 2008,
the estimated incidence of melanoma was 62,480; approxi-
mately 8420 deaths were attributable to this disease.2 Pa-
tients with metastatic melanoma have a median survival of
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The Journal of Thoracic and Cardiovascular SurThe standard treatment for patients with metastatic disease
is systemic interleukin 2 (IL-2) or chemotherapy.5-7
Response rates associated with these regimens are
relatively low, and complete responses are rare.
Translational research efforts by several groups through-
out the world, including the Surgery Branch, National Can-
cer Institute, have focused on the development of protocols
using adoptive cell transfer (ACT) of autologous tumor-
infiltrating lymphocytes (TIL) to augment immune-
mediated eradication of metastatic melanoma. TIL therapy
requires the resection of metastatic lesions to harvest
tumor-reactive T lymphocytes, which are selectively ex-
panded ex vivo and subsequently infused with high-dose
IL-2 into autologous lymphodepleted patients. Recent data
indicate clinical response rates exceeding 50% for patients
with melanoma undergoing ACT with autologous TIL.8
Because of the need for expeditious ex vivo expansion of
TIL cultures, an increasing number of patients with mela-
noma lacking bulky subcutaneous or lymph node metastases
have been referred for more extensive operations to harvestgery c December 2010
Abbreviations and Acronyms
ACT ¼ adoptive cell transfer
IL-2 ¼ interleukin 2
NED ¼ no evaluable disease
NMA ¼ nonmyeloablation
TBI ¼ total-body irradiation
TIL ¼ tumor-infiltrating lymphocyte
Klapper et al General Thoracic Surgery
G
T
Slesions sufficient for TIL production. However, as more in-
vasive procedures are performed to render patients with lim-
ited overall median survivals eligible for ACT protocols, the
potential risks and morbidities of metastasectomy must be
carefully assessed relative to the probabilities that these pa-
tients will receive and respond to TIL therapy. The present
study was undertaken to evaluate outcomes and potential
benefits of thoracic metastasectomy for adoptive immuno-
therapy of melanoma.
MATERIALS AND METHODS
Patients
A retrospective review of a prospectively collected database identified
patients who underwent thoracic metastasectomy for melanoma in the con-
text of immunotherapy from April 1998 to July 2009. All patients signed
institutional review board–approved consent forms for tissue procurement
and participation in subsequent immunotherapy protocols, if indicated. Pa-
tients with metastatic melanoma considered for experimental immunother-
apy were 18 years of age or older and negative for HIV and hepatitis B and
C, with a good performance status (Eastern Cooperative Oncology Group
class 2) and life expectancy greater than 3 months. Patients were enrolled
in sequential phase II protocols, the first 3 of which differed in terms of lym-
phodepletion regimens, whereas the fourth differed in terms of laboratory
preparation/analysis of TIL. All surgical procedures were performed by 3
surgeons (DSS, DMN, and KFK) in the Thoracic Oncology Section of
the Surgery Branch, National Cancer Institute.
Surgical Intervention and Continuing Care
Complete staging was performed with history and physical examination,
laboratory assessment, and computed tomographic examination of the
chest, abdomen, and pelvis. Additional studies were performed based on in-
dividual patient assessments. Patients did not necessarily have pathologic
confirmation of melanoma in the thorax before metastasectomy. Postopera-
tive pathology was confirmed in all patients. A patient’s suitability for tho-
racic resection was predicated on his or her ability to tolerate an operation,
pace of disease progression, absence of central nervous system or symptom-
atic intra-abdominal disease, and the likelihood of subsequently participat-
ing in an immunotherapy protocol. Ability to achieve a complete resection
was not a criterion for surgical intervention; indeed, the most common in-
dication was isolation of TIL in patients with widely metastatic disease. De-
cisions to operate were made on a case-by-case basis after thorough review
during a weekly multidisciplinary conference. The decision to resect all pul-
monary disease or simply harvest lesions sufficient for generating/
expanding TIL was determined preoperatively based on overall extent of
disease. In addition, central lesions associated with postobstructive atelecta-
sis or pneumonia were targeted for resection to simultaneously harvest TIL
and prevent potentially fatal septic complications during ACT. In essence,
the goal in patients with surgically incurable disease was to harvest a mini-
mum of 3 cm3 of viable tumor and resect obstructing lesions with minimalThe Journal of Thoracic and Carmorbidity to facilitate movement of these subjects to potentially curative
immunotherapy protocols. Patients rendered to no evaluable disease
(NED) status were evaluated every 3 months for the first year, every
6 months for the next 2 years, and annually thereafter.
TIL Production and Administration
After resection, all tumors were processed in the Cell Production Facility
of the Surgery Branch for isolation/expansion of TIL using previously
described techniques.9 Before July 2007, the activity and specificity of
expanded TIL were evaluated by means of cytokine release assays with
a panel of tumor targets, including allogeneic melanoma cell lines, fresh
autologous tumor cells (or autologous tumor cell lines when available),
and peptide-pulsed transporter associated with antigen processing–deficient
T2 cells. During that period, interferon g secretion by TIL appeared to cor-
relate with in vitro tumor cytotoxicity and in vivo efficacy. From July 2007
through July 2009, cultures that successfully yielded TIL were administered
without in vitro reactivity analysis given advancements in cell processing
and administration, and concerns that in vitro assays lacked sufficient sen-
sitivity and specificity to accurately reflect in vivo efficacy.10
TIL that met the criteria for infusion underwent rapid expansion with
OKT3 (anti-CD3) antibody (Ortho Biotech, Bridgewater, NJ), recombinant
IL-2 (Chiron Corp, Emeryville, Calif), and irradiated peripheral blood
mononuclear cells. After 14 days, these cells were harvested, and on
average, 6 3 1010 TIL were administered to autologous hosts by means
of a 30-minute intravenous infusion after nonmyeloablation (NMA)
with cyclophosphamide (60 mg $ kg1 $ d1 3 2 days) and fludarabine
(25 mg $m2 $ d13 5 days); several patients also received total-body irra-
diation (TBI) at a dose of 200 or 1200 cGy. After TIL infusion, most patients
received intravenous high-dose IL-2 up to 15 doses or until exhibiting dose-
limiting toxicity, which resolved in all patients within 7 days. Patients with
neutropenic fevers received antibiotics, which continued until full return of
immunologic function (typically 7 days). Under these regimens, the mini-
mum time from operation to TIL therapy was 6 to 8 weeks.
Assessment of Response
After cell transfer, patients were assessed radiographically for tumor
response by usingResponse EvaluationCriteria in Solid Tumors everymonth
for 6 months, every 3 months for a year, and every 6 months thereafter.11
Complete responders had no radiographic evidence of residual tumor after
therapy. Partial responders were patients exhibiting a 30% or greater decrease
in the sum of the longest diameters of their target lesions. Patients were
deemed tohave progressive disease if they exhibited a 20% or greater increase
in the sum of the longest diameters of their target lesions or had new lesions.
All radiographic images were reviewed independently by an attending
surgeon and a staff radiologist. Imaging studies of patients exhibiting an ob-
jective response were confirmed by at least 1 additional attending physician.
Statistical Analysis
Overall survival was calculated from the date of resection until the date
of last encounter or death. The date of first resection was used in patients
who underwent 2 operations. The probabilities of survival were calculated
by using Kaplan–Meier methods.RESULTS
From April 1998 until July 2009, 107 patients with meta-
static melanoma underwent 116 thoracic metastasectomy
procedures, including 9 patients who underwent 2 separate
procedures (Table 1). Ninety-six (90%) patients received
systemic treatment for metastatic melanoma before metasta-
sectomy. More than 50% of patients received high-dose
IL-2. Approximately 60% of patients received 2 differentdiovascular Surgery c Volume 140, Number 6 1277
TABLE 1. Clinical characteristics of 107 patients who underwent
thoracic metastasectomy for metastatic melanoma
Characteristic Value
Feature
No. of patients 107
Age, median (range) at operation (y) 47 (18–67)
Sex, M/F 61/46
Tobacco use
Yes 29 (27%)
No 78 (73%)
Prior treatment (per patient)
None 11 (10%)
Interferon alpha 2b 37 (35%)
Interleukin 2 65 (61%)
Adoptive cell transfer 15 (14%)
Chemotherapy 26 (24%)
Biochemotherapy* 15 (14%)
Vaccine 41 (38%)
Anti–CTLA-4 antibody 13 (12%)
Indication for metastasectomy (per case)
TIL 79 (68%)
NED 9 (8%)
Diagnosis 1 (1%)
Palliation of symptoms 2 (2%)
Progressive disease 4 (3%)
TIL/palliation 8 (7%)
TIL/NED 12 (10%)
TIL/diagnosis 1 (1%)
Surgical approach (per case)
Thoracotomy 69 (59%)
VATS 43 (37%)
Sternotomy 3 (3%)
Other 1 (1%)
Procedure (per case)
Lobectomy 23 (20%)
Nonanatomic (wedge) 66 (57%)
Segmentectomy 5 (4%)
Lingulectomy 1 (1%)
Pneumonectomy 2 (2%)
Chest wall resection 6 (5%)
Other 13 (11%)
Status after metastasectomy
Residual disease 90 (84%)
NED 17 (16%)
No. of metastases resected in patients
rendered to NED statusy
1 13
2 4
3 2
CTLA-4, Cytotoxic T lymphocyte–associated antigen 4; TIL, tumor-infiltrating lym-
phocytes; NED, no evaluable disease; VATS, video-assisted thoracoscopic surgery.
*Biochemotherapy ¼ chemotherapy combined with interleukin 2 or interferon a.
yIncludes 2 patients rendered NED twice (n ¼ 19).
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including chemotherapy, immunotherapy, vaccines, or
investigational agents in various combinations. Fifteen
patients were treated with ACT of autologous TIL or genet-1278 The Journal of Thoracic and Cardiovascular Surically engineered peripheral blood lymphocytes before
metastasectomy; 3 of these patients were retreated with
TIL after thoracic metastasectomy. There was 1 postopera-
tive death caused by pulmonary embolism and 1
coagulopathy-induced hemothorax treated with recombi-
nant activated Factor VII and evacuation of clot in a patient
undergoing pneumonectomy for postobstructive pneumonia
and hemodynamically significant mediastinal compression.
Morbidities, such as atrial arrhythmia, persistent air leak,
or pneumonia, were exceedingly rare (low single digits),
possibly due to lower median age, less tobacco exposure, ab-
sence of significant cardiopulmonary comorbidities, and im-
proved overall performance status of the immunotherapy
protocol candidates relative to patients typically
undergoing lung cancer resections.12,13
The most common single indication for surgical interven-
tion was procurement of TIL (79/116 [68%]). Frequently,
the indications for surgical intervention overlapped. Addi-
tional indications, included resection to NED (21/116
[18%]), diagnosis (2/116 [2%]), solitary site of progressive
disease after systemic therapy (4/116 [3%]), and palliation
of hemoptysis, bronchial obstruction, hemothorax, and/or
pleural effusion (10/116 [9%]). Eight of the 10 patients re-
quiring surgical intervention for palliation had TIL cultures
established from the resection specimens.
One hundred one tumor specimens from 116 procedures
were cultured for TIL. Of the 15 tumors not cultured for
TIL, 8 patients were resected to NED, and 2 had rapid
progression of disease, death, or both; 5 tumors were not
processed for unknown reasons (possibly because of the
small size of the lesions). Ninety-three (92%) of 101 TIL
cultures were considered growth positive (Table 2).
Sixty-nine growth-positive cultures were tested for activity,
47 (68%) of which were reactive based on laboratory crite-
ria. Twenty-four cases of growth-positive TIL were not
tested because the respective patients had stable disease,
were rendered to NED status, or were excluded because of
significant disease progression or treatment on an alternate
immunotherapy protocol. For 7 patients treated after July
2007, growth-positive TIL cultures were not tested for in vi-
tro tumor reactivity because of the aforementioned modifica-
tions of TIL expansion protocols. Twenty-four (26%)
patients with residual disease, including 1 patient who was
rendered to NED status and subsequently had recurrent dis-
ease, were treated on various TIL protocols (Figure 1).
The reasons patients did not receive TIL are listed in Table
2. Patients with tumor cultures that did not grow TIL or
growth-positive cultures that did not meet the criteria for re-
activity before July 2007 were unable to be treated. Despite
having reactive TIL, some patients did not undergo ACT be-
cause of rapid, uncontrollable disease progression (typically
involving the spine or central nervous system with symp-
toms or potential risk of bleeding while thrombocytopenic,
gastrointestinal tract with bleeding or obstruction, or newgery c December 2010
TABLE 2. Results of TIL growth, testing, and therapy
Characteristic Value
No. of tumor specimens obtained 116
Cultured 101
Not cultured 15
TIL growth (per specimen cultured)
Positive 93 (92%)
Negative 8 (8%)
TIL activity tested 69
Reactive 47 (68%)
Nonreactive 22 (32%)
TIL activity not tested 24
Treatments after metastasectomy (per patient)
TIL 24
No TIL 83
Reasons for no TIL treatment*
Progressive disease 25 (27%)
TILs not reactive in vitro 20 (22%)
NED 18 (20%)
Alternate protocol assignment 8 (9%)
TILs did not grow 6 (7%)
Protocol exclusion 4 (4%)
Stable disease 3 (3%)
Death 3 (3%)
Unknown 5 (5%)
Objective response to TILs
Complete response 2
Partial response 5
No response 15
Not evaluable for response 2
TIL, Tumor-infiltrating lymphocyte; NED, no evaluable disease. *There were 92 in-
stances in which TIL therapy was considered, including 9 patients who were resected
twice.
FIGURE 1. Flow diagram of patients undergoing thoracic metastasectomy
for melanoma immunotherapy. Patients are classified according to status of
tumor-infiltrating lymphocyte (TIL) culture, TIL growth, TIL activity in vi-
tro, and treatment with TIL or not. aTIL cultures per procedure. bIncludes
resection, and no treatment twice for 1 patient. cOne patient included in
each group because of first resection and treatment followed by recurrence,
and second resection and no subsequent treatment. dRepresentative of 24 in-
dividual patient’s treatments.
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fections, all of which were exclusion criteria for TIL proto-
cols), death, alternate protocol assignment, or NED status.
Before July 2007, the average time from operation to treat-
ment with TIL was 6 to 8 weeks. During TIL expansion, pa-
tients did not receive systemic treatment for melanoma, and
many had rapidly progressive disease, as noted above, or ex-
hibited a significant decrease in performance status resulting
in protocol ineligibility or death. The advent of short-term
TIL culture techniques and the elimination of in vitro testing
before treatment shortened the interval from operation to
TIL therapy by approximately 2 weeks. Of the 26 patients
who underwent thoracic metastasectomy after July 2007,
the proportion of patients receiving ‘‘young’’ TIL without
assessment of in vitro tumor reactivity (8/26 [31%]) was
somewhat higher than that of the preceding cohort receiving
‘‘conventional’’ TILs (16/82 [20%]). One patient under-
went surgical intervention in both cohorts.
Seventeen patients were rendered to NED status at the
time of surgical intervention. The number of metastatic
lesions removed was 1 in 13 cases, 2 in 4 cases, and 3 or
more in 2 cases. Two patients had a recurrence more thanThe Journal of Thoracic and Car1 year after their operations, and underwent repeat thoracic
metastasectomy to render them free of disease again. One
patient who was rendered to NED status after metastasec-
tomy had recurrent disease 5 months later and was treated
with TIL. Because the intent of that procedure was not
only to remove all gross tumor but also to generate TIL,
this patient is included in the TIL group for survival analysis.
Although 10 of the remaining 16 patients rendered to NED
status at the time of metastasectomy had tumor specimens
cultured for TIL, this group was never treated with TIL
and is considered separately in analysis of survival.
Of the 24 patients receiving TIL therapy, 2 had complete
responses and 5 had partial responses, for an overall
treatment response rate of 29%. Based on preoperative
intent-to-treat, patients with residual or recurrent disease,
the overall response rate was 8% (7/91). Sixteen patients
had no response to treatment. Six (35%) of 17 patients
treated with conventional TIL compared with 1 (14%) of 7
receiving young TIL exhibited objective responses. Two pa-
tients were not evaluable, one because of treatment-related
mortality and the other because of treatment proximate to
this analysis. Aside from the single treatment-related mortal-
ity, toxicities associated with ACT were reversible anddiovascular Surgery c Volume 140, Number 6 1279
FIGURE 2. A, Overall survival of 107 patients undergoing thoracic metastasectomy for melanoma immunotherapy. The median survival was 13.2 months,
with a 5-year survival rate of 22%. B, Survival of patients rendered to no evaluable disease (NED) status after surgical intervention. The median survival for
these patients has not been reached. C, Survival of patients with residual disease after metastasectomy who received tumor-infiltrating lymphocyte (TIL) ther-
apy. Median survival of these patients was 14 months. D, Survival of patients with residual disease after metastasectomy who did not receive TIL therapy.
Median survival of these patients was 10 months.
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The median survival for all patients in this study was 13.2
months (Figure 2, A). As of January 15, 2010, the median
survivals for patients who received TIL and those who did
not receive TIL were 14 and 10 months, respectively. The
median survival for patients undergoing potentially curative
resections has not been reached. Actuarial 1- and 5-year sur-
vival rates for patients rendered to NED status, receiving
TIL, or not receiving TIL, were 93% and 76%, 64% and
33%, and 43% and 0%, respectively (Figure 2, B–D,
respectively).
DISCUSSION
Whereas approved chemotherapeutic regimens as well as
targeted molecular agents for metastatic melanoma afford
patients limited chance for long-term survival,6,14 ongoing
research in cancer immunology offers hope for patients
with this disease. Presently, approximately 15% of
patients treated with high-dose IL-2 exhibit objective tumor1280 The Journal of Thoracic and Cardiovascular Surregressions, half of which are durable complete responses.15
Similar response rates have been observed in patients with
melanoma after monoclonal antibody blockade of cytotoxic
T lymphocyte–associated antigen 4.16,17
The response of metastatic melanoma to immunotherapy
provides the impetus for refinement of cell-based regimens
for patients with this disease.18 Dudley and colleagues8 re-
ported results pertaining to 93 patientswithmelanoma treated
with TILs after several lymphodepletion regimens; response
rates were 48%, 52%, and 72% for NMA, NMA plus 200
cGy TBI, and NMA plus 1200 cGy TBI, respectively. Be-
cause tumor reactivity was a prerequisite for treatment on
these protocols, each patient’s TIL culture underwent an in-
dividualized screening assay. Tumor progression during the
extended time for TIL production or a negative tumor reactiv-
ity screen result rendered approximately 73%of patientswho
underwent tissue procurement ineligible for ACT.
Because of improved responses to immunotherapy in se-
quential clinical trials within the Surgery Branch, efforts togery c December 2010
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procedures once considered unconscionable for patients
with disseminated melanoma. To the best of our knowledge,
this article is the first reported experience pertaining to
patients with melanoma undergoing thoracic metastasec-
tomy solely in the context of experimental immunotherapy
protocols. Unlike other reported series,19-21 in our study
metastasectomy was performed in most patients not to
render them to NED status but to facilitate their eligibility
for ACT. Despite these highly focused efforts, relatively
few patients with residual disease ultimately underwent
ACT, primarily because of lack of TIL reactivity or rapidly
progressive disease. This is unfortunate because patients
who received TIL infusions after thoracic metastasectomy
had a 5-year actuarial survival of 33%, whereas none of
those who did not undergo ACT survived 5 years. The fact
that response rates after TIL therapy in our series are lower
than those reported byDudley and colleagues8 may be attrib-
utable to the relatively low number of patients treated, as well
as suboptimal TIL production and host preparative regimens
(only approximately 25% of patients received TBI), high-
lighting the clinical relevance of the evolution of TIL efforts
in the Surgery Branch.
Although thoracic metastasectomy was associated with
low mortality and minimal morbidity, the fact that relatively
few patients in our study ultimately received TIL therapy rai-
ses concerns regarding the ethics of subjecting patients with
advanced malignancies and limited life expectancies to inva-
sive procedures in the context of highly experimental treat-
ment protocols, particularly in an era of dwindling health
care resources.22 On the other hand, our experience demon-
strates an evolving role of thoracic surgery in facilitating de-
velopment of innovative systemic cancer regimens.
Furthermore, our data highlight the fact that patients consid-
ered for protocols contingent on procured tumor specimens
must be fully appraised of the potential risks and morbidities
of their respective surgical procedures, as well as the likeli-
hood that they will receive and ultimately respond to inves-
tigational therapy, to make informed decisions regarding
their care.23
Results of this analysis are consistent with data pertaining
to a recent unpublished evaluation of metastasectomy and
TIL therapy within the Surgery Branch. Between 2002 and
2007, 402 patients underwent 541 procedures, yielding via-
ble and reactive TIL in 376 (94%) and 269 (67%) patients,
respectively; 107 (27%) patients underwent ACT. In light of
the collective experience, considerable efforts have been un-
derway within the Surgery Branch to optimize TIL produc-
tion. A recent series of experiments revealed that minimally
cultured TIL exhibited optimal characteristics for ACT, in-
cluding tumor reactivity,10 which obviated the requirement
for in vitro screening that previously disqualified patients
from receiving therapy. Translation of these observations
to a phase II clinical trial for the treatment of patients withThe Journal of Thoracic and Carmelanoma using minimally cultured TIL resulted in higher
patient recruitment rates, shorter times between resection
and treatment, and response rates comparable with those
seen with conventional TIL (Dudley and colleagues, submit-
ted for publication). These data suggest that an additional 20
patients or more in our study who did not undergo ACT be-
cause of a lack of TIL reactivity or rapid disease progression
might have been candidates for potentially beneficial TIL
therapy. Ongoing efforts are focused on identification of
prognostic and predictive markers to improve patient selec-
tion and further optimization of TIL protocols to enhance
overall response rates, thereby minimizing the number of
futile metastasectomy procedures.
Approximately 25% of patients with melanoma have
pulmonary metastases, resection of which was proposed as
potentially beneficial before the advent of effective systemic
therapy.24 More recent studies have confirmed the benefit of
complete resection in patients with melanoma with oligome-
tastatic disease involving the lungs; in the absence of effec-
tive systemic therapy, the role of metastasectomy remains
limited for the majority of patients with disseminated
melanoma.19,21,25 Our data are consistent with these
observations. Although the goal of our study was to review
the potential utility of thoracic metastasectomy as a means
to render patients eligible for adoptive immunotherapy
rather than definitive treatment for metastatic melanoma, it
is noteworthy that 17 patients in our study underwent
resection of all evaluable disease, with 12 alive today
(Figure 1). The 5-year actuarial survival (76%) of this group
exceeds that reported for patients undergoing complete re-
section in other series.19,21,25 Whereas these findings are
certainly attributable in part to patient selection, it is
intriguing that 15 of these patients had received some form
of immunotherapy (IL-2, vaccine, or interferon) before
undergoing resection. One patient who was rendered to
NED status subsequently had recurrent disease that was
treated with TIL. This patient’s experience highlights the
potential value of cryopreserving melanoma lesions for
future immunotherapy protocols given the high likelihood
of disease recurrence.
Potential limitations of this study include the retrospective
manner of data analysis, as well as selection bias inherently
resulting from the fact that patients were not prospectively
randomized to treatment regimens; these issues limit firm
conclusions regarding survival rates. Inevitably, patients
with slowly growing metastases and good performance sta-
tus exhibited a more favorable tumor biology, which enabled
them to be referred for thoracic metastasectomy and undergo
TIL therapy. In contrast, patients unable to receive TIL
therapy had more aggressive tumors that might have been
refractory to any interventions.
Despite the fact that patients referred for surgical interven-
tion were highly selected, this experience is noteworthy for
demonstrating the potential benefits of TIL therapy in patientsdiovascular Surgery c Volume 140, Number 6 1281
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thoracic metastasectomy cannot be routinely advocated for
patients expected to have residual disease, these operations
might yield TIL that can mediate durable tumor regressions.
Given the encouraging results of TIL therapy,8 patients
with melanoma with thoracic metastases should be referred
to centers of excellence in cancer immunotherapy to deter-
mine their eligibility for potentially curative ACT protocols.
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